Michael Pisetsky Sells 3,726 Shares of SiBone (NASDAQ:SIBN) Stock

SiBone (NASDAQ:SIBN) SVP Michael Pisetsky sold 3,726 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $14.63, for a total value of $54,511.38. Following the completion of the sale, the senior vice president directly owned 280,509 shares of the company’s stock, valued at approximately $4,103,846.67. This trade represents a 1.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Stock Down 0.1%

SIBN traded down $0.02 during trading on Wednesday, reaching $14.82. 506,954 shares of the stock traded hands, compared to its average volume of 666,784. The stock has a market cap of $657.25 million, a price-to-earnings ratio of -38.00 and a beta of 0.67. SiBone has a fifty-two week low of $11.48 and a fifty-two week high of $21.89. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The stock’s 50-day simple moving average is $13.35 and its two-hundred day simple moving average is $16.10.

SiBone (NASDAQ:SIBN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. The firm had revenue of $52.59 million during the quarter, compared to analysts’ expectations of $51.16 million. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%. As a group, equities research analysts expect that SiBone will post -0.44 EPS for the current year.

Institutional Trading of SiBone

Institutional investors and hedge funds have recently made changes to their positions in the stock. ANTIPODES PARTNERS Ltd acquired a new stake in shares of SiBone in the fourth quarter worth about $29,000. Royal Bank of Canada lifted its position in shares of SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of SiBone by 64,700.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after buying an additional 1,941 shares during the last quarter. State of Alaska Department of Revenue acquired a new stake in shares of SiBone in the third quarter worth about $39,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of SiBone in the fourth quarter worth about $53,000. Institutional investors and hedge funds own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SIBN shares. Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a research report on Saturday, April 18th. TD Cowen reduced their price objective on SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Finally, Truist Financial reissued a “buy” rating and set a $18.00 price objective (down from $20.00) on shares of SiBone in a research report on Tuesday, May 12th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.